An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma

We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian male who was diagnosed with stage IV-M1a melanoma. He was initially treated with pembrolizumab monotherapy (Q3W) and had a complete response after 14 cycles. However, relapse was suspected 3 months later with appearance of hilar, mediastinal and hepatic hilar lymph nodes as well as a skin lesion. Biopsy of both the hilar lymph nodes and the skin lesion demonstrated sarcomatoid granulomatosis. Pembrolizumab was discontinued temporarily. While on 18F-FDG-PET/CT, all sarcoid-like lesions regressed in size and activity, a new hypermetabolic solitary skeletal lesion was detected in a lumbar vertebra, suspicious for metastasis. However, since the patient was asymptomatic, a watchful-waiting attitude was taken. During this period, a spontaneous and complete resolution of the metabolic activity was observed of the skeletal lesion. Until today, the patient remains in complete remission. Current case presents an atypical presentation and evolution of anti-PD-1-induced sarcoid-like reaction, illustrating the difficulty of differentiating it from disease progression. Before considering (re-)initiation of anti-melanoma therapy, a tissue biopsy of one of the suspected lesions may be performed to confirm diagnosis. Physicians treating patients with ICI should be aware of this difficulty and critically assess the nature of lesions suspect of progression in patients responding to ICI and presenting with a sarcoid-like reaction.

[1]  D. Pisetsky,et al.  Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors , 2019, Rheumatology.

[2]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[3]  H. Tran,et al.  Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma , 2019, Case Reports in Oncology.

[4]  L. Hakim-Meibodi,et al.  18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab , 2019, Melanoma research.

[5]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[6]  G. Prévot,et al.  Granulomatose sarcoïdosique survenant sous inhibiteurs de point de contrôle immunitaire , 2018, Revue des Maladies Respiratoires.

[7]  K. Syrigos,et al.  Sarcoidosis‐Like Reactions Induced by Checkpoint Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  L. Ny,et al.  Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. , 2018, The Lancet. Oncology.

[9]  C. Balleyguier,et al.  Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. , 2018, European journal of cancer.

[10]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[11]  R. Braun,et al.  Sarcoid-like reactions in patients receiving modern melanoma treatment , 2018, Melanoma research.

[12]  B. Firwana,et al.  Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[13]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[14]  K. Shannon,et al.  Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: Case series and immunophenotypic analysis , 2017, International journal of rheumatic diseases.

[15]  Paul R. Kunk,et al.  Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature , 2016, Journal of Immunotherapy for Cancer.

[16]  C. Querfeld,et al.  Pembrolizumab-associated sarcoidosis , 2016, JAAD case reports.

[17]  I. Svane,et al.  Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab , 2014, Oncoimmunology.

[18]  A. Prasse,et al.  Sarcoidosis , 2014, The Lancet.

[19]  B. Neyns,et al.  Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. , 2012, Anticancer research.

[20]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.